With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

In conjunction with the Seagen acquisition, Pfizer shifted its oncology focus from chemically made small-molecule drugs to ...